Matthew J. Ellis

65.5k total citations · 13 hit papers
321 papers, 26.9k citations indexed

About

Matthew J. Ellis is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, Matthew J. Ellis has authored 321 papers receiving a total of 26.9k indexed citations (citations by other indexed papers that have themselves been cited), including 184 papers in Oncology, 162 papers in Cancer Research and 102 papers in Genetics. Recurrent topics in Matthew J. Ellis's work include Breast Cancer Treatment Studies (115 papers), Estrogen and related hormone effects (91 papers) and HER2/EGFR in Cancer Research (83 papers). Matthew J. Ellis is often cited by papers focused on Breast Cancer Treatment Studies (115 papers), Estrogen and related hormone effects (91 papers) and HER2/EGFR in Cancer Research (83 papers). Matthew J. Ellis collaborates with scholars based in United States, Canada and United Kingdom. Matthew J. Ellis's co-authors include Charles M. Perou, Daniel F. Hayes, X. Cynthia, G. Thomas Budd, Jeri Matera, Leon W.M.M. Terstappen, Michael Craig Miller, Joel S. Parker, Gerald V. Doyle and Massimo Cristofanilli and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Matthew J. Ellis

309 papers receiving 26.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer

2004 3.5k citations Matthew J. Ellis, Daniel F. Hayes et al. New England Journal of Medicine profile →
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

2009 3.1k citations Joel S. Parker, Michael E. Mullins et al. Journal of Clinical Oncology profile →
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

2009 1.6k citations Maggie C.U. Cheang, Stephen Chia et al. JNCI Journal of the National Cancer Institute profile →
CDK4/6 inhibition triggers anti-tumour immunity

2017 998 citations Jeremy Hoog, Matthew J. Ellis et al. profile →
Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival

2006 808 citations Daniel F. Hayes, Matthew J. Ellis et al. Clinical Cancer Research profile →
Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial

2001 790 citations Matthew J. Ellis et al. Journal of Clinical Oncology profile →
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer

2012 600 citations Ron Bose, Shyam M. Kavuri et al. profile →
Long noncoding RNA MALAT1 suppresses breast cancer metastasis

2018 546 citations Matthew J. Ellis et al. profile →
A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer

2010 542 citations Torsten O. Nielsen, Joel S. Parker et al. Clinical Cancer Research profile →
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

2001 530 citations Matthew J. Ellis et al. profile →
Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

2005 503 citations Matthew J. Ellis et al. Journal of Clinical Oncology profile →
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer

2015 458 citations Matthew J. Ellis, Lisa A. Carey et al. New England Journal of Medicine profile →
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial

2016 384 citations J.F.R. Robertson, Zhimin Shao et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matthew J. Ellis United States	65	15.9k	13.1k	9.0k	6.7k	4.7k	321	26.9k
Jonas Bergh Sweden	73	15.6k 1.0×	11.6k 0.9×	11.2k 1.2×	4.9k 0.7×	3.3k 0.7×	521	29.1k
Lars A. Akslen Norway	67	14.0k 0.9×	11.6k 0.9×	13.8k 1.5×	4.4k 0.7×	3.3k 0.7×	314	29.1k
Ana M. González-Angulo United States	83	15.2k 1.0×	11.4k 0.9×	8.9k 1.0×	5.2k 0.8×	2.6k 0.5×	281	25.2k
Edith A. Perez United States	79	20.7k 1.3×	11.1k 0.8×	6.6k 0.7×	5.8k 0.9×	4.4k 0.9×	400	30.1k
Stefanie S. Jeffrey United States	51	13.8k 0.9×	14.9k 1.1×	16.6k 1.8×	3.9k 0.6×	4.7k 1.0×	138	33.6k
John A. Foekens Netherlands	79	11.4k 0.7×	10.6k 0.8×	13.5k 1.5×	3.6k 0.5×	3.3k 0.7×	337	25.5k
Charles Swanton United Kingdom	79	12.8k 0.8×	12.7k 1.0×	13.0k 1.4×	8.5k 1.3×	2.2k 0.5×	325	30.6k
Stephen B. Fox Australia	84	13.0k 0.8×	10.4k 0.8×	14.2k 1.6×	4.7k 0.7×	2.9k 0.6×	423	29.3k
Lajos Pusztai United States	87	20.1k 1.3×	16.9k 1.3×	12.1k 1.3×	5.7k 0.8×	2.9k 0.6×	591	35.0k
Jorge S. Reis‐Filho United States	100	18.0k 1.1×	16.4k 1.3×	17.1k 1.9×	6.0k 0.9×	4.2k 0.9×	521	37.9k

Countries citing papers authored by Matthew J. Ellis

Since Specialization

Citations

This map shows the geographic impact of Matthew J. Ellis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew J. Ellis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew J. Ellis more than expected).

Fields of papers citing papers by Matthew J. Ellis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew J. Ellis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew J. Ellis. The network helps show where Matthew J. Ellis may publish in the future.

Co-authorship network of co-authors of Matthew J. Ellis

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew J. Ellis. A scholar is included among the top collaborators of Matthew J. Ellis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew J. Ellis. Matthew J. Ellis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ma, Jennifer, Rachna Shah, Andrew Bell, et al.. (2024). Increased Synthetic Cytotoxicity of Combinatorial Chemoradiation Therapy in Homologous Recombination Deficient Tumors. International Journal of Radiation Oncology*Biology*Physics. 121(3). 768–779.

Ephraim, Patti L., Clemontina A. Davenport, Lisa M. McElroy, et al.. (2023). Association of Age and Gender With Concerns About Live Donor Kidney Transplantation Among Black Individuals. Transplantation Proceedings. 55(10). 2403–2409. 1 indexed citations

Suman, Vera J., Lili Du, Tanya L. Hoskin, et al.. (2022). Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031). Clinical Cancer Research. 28(15). 3287–3295. 12 indexed citations

Kalra, Rashi, Junkai Wang, Ahmad Bin Salam, et al.. (2022). Poziotinib Inhibits HER2-Mutant–Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer. Cancer Research. 82(16). 2928–2939. 10 indexed citations

Brenelli, Fabrício Palermo, Tomás Reinert, Antônio Luiz Frasson, et al.. (2021). Real-world data on neoadjuvant endocrine therapy in ER-positive/HER2-negative breast cancer. Breast Cancer Research and Treatment. 186(3). 753–760. 6 indexed citations

Li, Xiang, Richard Davis, Zehan Wang, et al.. (2021). Deep learning segmentation of glomeruli on kidney donor frozen sections. Journal of Medical Imaging. 8(6). 67501–67501. 16 indexed citations

Cynthia, X., Vera J. Suman, A. Marilyn Leitch, et al.. (2020). ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106.. Journal of Clinical Oncology. 38(15_suppl). 504–504. 27 indexed citations

Noguchi, Shinzaburo, Matthew J. Ellis, J.F.R. Robertson, et al.. (2018). Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON). Breast Cancer. 25(3). 356–364. 12 indexed citations

Doostan, Iman, Cansu Karakaş, Matthew J. Ellis, et al.. (2017). Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer. Clinical Cancer Research. 23(23). 7288–7300. 35 indexed citations

10.

Ben-Baruch, Noa, Ron Bose, Shyam M. Kavuri, X. Cynthia, & Matthew J. Ellis. (2015). HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor. Journal of the National Comprehensive Cancer Network. 13(9). 1061–1064. 57 indexed citations

11.

Cynthia, X., Jingqin Luo, Michael Naughton, et al.. (2015). A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer. Clinical Cancer Research. 22(7). 1583–1591. 77 indexed citations

12.

Xu, Siguang, Shunqiang Li, Zhanfang Guo, et al.. (2013). Combined Targeting of mTOR and AKT Is an Effective Strategy for Basal-like Breast Cancer in Patient-Derived Xenograft Models. Molecular Cancer Therapeutics. 12(8). 1665–1675. 41 indexed citations

13.

Nielsen, Torsten O., Joel S. Parker, Samuel Leung, et al.. (2010). A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer. Clinical Cancer Research. 16(21). 5222–5232. 542 indexed citations breakdown →

14.

Parker, Joel S., Michael E. Mullins, Maggie C.U. Cheang, et al.. (2009). Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. Journal of Clinical Oncology. 27(8). 1160–1167. 3093 indexed citations breakdown →

15.

Cheang, Maggie C.U., Stephen Chia, David Voduc, et al.. (2009). Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer. JNCI Journal of the National Cancer Institute. 101(10). 736–750. 1641 indexed citations breakdown →

16.

Crowder, Robert J., Chanpheng Phommaly, Tao Yu, et al.. (2009). PIK3CA and PIK3CB Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor–Positive Breast Cancer. Cancer Research. 69(9). 3955–3962. 174 indexed citations

17.

Ellis, Matthew J. & X. Cynthia. (2007). Letrozole in the neoadjuvant setting: the P024 trial. Breast Cancer Research and Treatment. 105(S1). 33–43. 82 indexed citations

18.

Hayes, Daniel F., Ann D. Thor, Lynn G. Dressler, et al.. (2007). HER2 and Response to Paclitaxel in Node-Positive Breast Cancer. New England Journal of Medicine. 357(15). 1496–1506. 403 indexed citations

19.

Harris, Lyndsay N., Gloria Broadwater, Nancy U. Lin, et al.. (2006). Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Research. 8(6). 123 indexed citations

20.

Ellis, Matthew J.. (2004). Overcoming Endocrine Therapy Resistance by Signal Transduction Inhibition. The Oncologist. 9(S3). 20–26. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact